The main factor anticipated to propel market expansion over the forecast period is the high prevalence of chronic pain in adults. The number of persons who experience chronic pain on a global scale is very great. This is expected to fuel the expansion of the worldwide opioid market. For instance, in 2019, 7.4% of Americans reported having high-impact chronic pain, according to the National Health Interview Survey (NHIS) from the Centers for Disease Control and Prevention (CDC). Market participants are concentrating on the release of generic versions of opioid drugs, which is anticipated to accelerate market growth throughout the forecast period. For instance, in December 2016, Amneal Pharmaceuticals' Impax Laboratories, Inc., a division, introduced a generic version of Kadian (morphine sulphate) Extended Release Capsules, USP CII 20, 30, 50, 60, 80, and 100 mg. These capsules are intended to treat severe persistent pain.
According to Coherent Market Insights, the worldwide Opioids Drugs Market is anticipated to reach US$ 42,429 Mn in 2021 and grow at a CAGR of 3.2% during the projected period (2021-2028).
Prominent Players in the Opioid Drugs Industry:
1. Teva Pharmaceutical Industries Ltd.
Israel's Tel Aviv serves as the company's headquarters, which was formed in 1901. Generic medications are its main area of expertise, but it also has certain additional business interests in active pharmaceutical ingredients and, to a lesser extent, patented pharmaceuticals. In January 19, 2023, the Science Based Targets programme (SBTi) will have externally validated Teva's ambitious climate targets. Following receiving widespread support from the states, Teva announced on January 9th, 2023 that the nationwide opioids settlement will proceed.
2. Johnson & Johnson,
Johnson & Johnson was established in 1886 and has its corporate headquarters in New Brunswick, New Jersey. Medical technology, prescription drugs, and consumer packaged goods are all developed by Johnson & Johnson. In November 2021, the business stated that it would divide into two publicly listed businesses, one specialising on consumer goods and the other in medicines and medical technologies. The business claimed that its Covid-19 vaccination generated $100 million in sales in the first quarter in April 2021. Johnson & Johnson paid $16.6 billion to acquire Abiomed Inc. in November 2022.
3. Mallinckrodt Pharmaceuticals
In St. Louis in 1867, the company Mallinckrodt was founded. Although the operational offices of Mallinckrodt are in the United States, the company's tax headquarters are in Ireland. Mallinckrodt purchases products (for price changes), manufactures goods, and distributes for use in diagnosing, treating, and managing pain and associated diseases. For the treatment of hepatorenal syndrome, Mallinckrodt announced in June 2022 that Terlipressin would be resubmitted to the FDA. Mallinckrodt was given permission to list on the NYSE American in October 2022.
